April 29, 2026 —
Ray Therapeutics has received Priority Medicines (PRIME) designation from the European Medicines Agency for its lead candidate RTx-015, reinforcing growing regulatory momentum for the company’s AAV-based optogenetic gene therapy in Retinitis Pigmentosa.
The PRIME designation follows a recent Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, positioning RTx-015 among a select group of therapies recognized on both sides of the Atlantic for their potential to address significant unmet medical needs.
RTx-015 represents a novel approach to vision restoration. Unlike traditional gene therapies that aim to replace a defective gene, RTx-015 is a genotype-independent optogenetic therapy designed to restore light sensitivity in retinal cells through a single intravitreal injection. The therapy utilizes an engineered Adeno-associated virus (AAV)—specifically the AAV.7m8 capsid licensed from Adverum Biotechnologies—to deliver light-sensitive proteins to surviving retinal cells.
This strategy is particularly important in advanced RP, where photoreceptor cells are largely lost and traditional gene replacement approaches may no longer be viable. By bypassing the need for functional photoreceptors, optogenetics opens a potential path to restore vision even in late-stage disease.
The PRIME designation was supported by early clinical data from an ongoing Phase 1/2 trial, where improvements in vision were observed across all dose levels in treated eyes. These preliminary findings suggest that RTx-015 could meaningfully impact visual function in a patient population with no approved therapeutic options.
Retinitis pigmentosa affects more than one million people globally and is characterized by progressive degeneration of rod and cone photoreceptors, ultimately leading to severe vision loss or blindness. Despite its genetic complexity, there are currently no broadly effective treatments for advanced disease.
Regulatory designations such as PRIME and RMAT are designed to accelerate development timelines through enhanced agency interaction, optimized trial design guidance, and potential pathways to earlier approval. For RTx-015, dual recognition from both EMA and FDA signals strong confidence in both the underlying science and early clinical performance.
More broadly, the program highlights the continued evolution of AAV gene therapy beyond gene replacement, with optogenetics emerging as a powerful modality for restoring function in degenerative diseases where cells are lost rather than simply dysfunctional.
